When to start anticoagulation after acute ischemic stroke

Valeria Caso
Stroke Unit
Ospedale Santa Maria della Misericordia, Perugia

RAF NOACs study: Outcome events (ischemic and hemorrhagic) depending on the time between onset and initiation of therapy with NOACs.

- 1127 patients with acute stroke and AF
- 32 (2.8%) ischemic recurrences (IS –TIA – SE) at 90 days
- 18 (1.6%) symptomatic ICH



Risk of combined outcome events based upon the day of initiating NOAC

Paciaroni et al, JAHA 2017

Circulation

ORIGINAL RESEARCH ARTICLE

Early Versus Delayed Non–Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study

Jonas Oldgren, MD, PhD*; Signild Åsberg, MD, PhD*; Ziad Hijazi, MD, PhD; Per Wester, MD, PhD; Maria Bertilsson, MSc; Bo Norrving, MD, PhD; for the National TIMING Collaborators



Figure 2. Risk difference in the primary composite outcome for early vs delayed initiation of NOAC at 90 days.
Primary outcome was a composite of ischemic stroke, symptomatic intracerebral hemorrhage, or all-cause mortality. Primary hypothesis testing for noninferiority at an absolute 3% margin, and secondary hypothesis testing for superiority. NOAC indicates non–vitamin K antagonist oral anticoagulant.

Oldegren et al; Circulation 2022

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Early versus Later Anticoagulation for Stroke with Atrial Fibrillation

U. Fischer, M. Koga, D. Strbian, M. Branca, S. Abend, S. Trelle, M. Paciaroni, G. Thomalla, P. Michel, K. Nedeltchev, L.H. Bonati, G. Ntaios, T. Gattringer, E.-C. Sandset, P. Kelly, R. Lemmens, P.N. Sylaja, D. Aguiar de Sousa, N.M. Bornstein, Z. Gdovinova, T. Yoshimoto, M. Tiainen, H. Thomas, M. Krishnan, G.C. Shim, C. Gumbinger, J. Vehoff, L. Zhang, K. Matsuzono, E. Kristoffersen, P. Desfontaines, P. Vanacker, A. Alonso, Y. Yakushiji, C. Kulyk, D. Hemelsoet, S. Poli, A. Paiva Nunes, N. Caracciolo, P. Slade, J. Demeestere, A. Salerno, M. Kneihsl, T. Kahles, D. Giudici, K. Tanaka, S. Räty, R. Hidalgo, D.J. Werring, M. Göldlin, M. Arnold, C. Ferrari, S. Beyeler, C. Fung, B.J. Weder, T. Tatlisumak, S. Fenzl, B. Rezny-Kasprzak, A. Hakim, G. Salanti, C. Bassetti, J. Gralla, D.J. Seiffge, T. Horvath, and J. Dawson, for the ELAN Investigators*

Primary outcome at 30 and 90 days



N Engl J Med 23 May, 2023